Holen Sie sich die Stockscreener-App
35.17
0.80%
0.28
Handel nachbörslich:
35.17
Schlusskurs vom Vortag:
$34.89
Offen:
$35.01
24-Stunden-Volumen:
1.19M
Relative Volume:
0.59
Marktkapitalisierung:
$7.25B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$424.88M
KGV:
17.21
EPS:
2.0439
Netto-Cashflow:
$447.20M
1W Leistung:
+6.64%
1M Leistung:
-12.01%
6M Leistung:
-24.91%
1J Leistung:
-16.90%
1-Tages-Spanne:
$34.96
$35.43
1-Wochen-Bereich:
$32.94
$35.43
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
35.17 | 7.20B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen N.V. stock (NL0012169213): Jefferies cuts target as diagnostics group navigates post-pandemic - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): oncology ramp and new diagnostics deals put focus on growth mix - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. stock (NL0012169213): Legal probes and price drop unsettle investors - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics group updates investors after solid Q1 2026 - AD HOC NEWS
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
Qiagen N.V. Stock 12‑Month Price Target Cut to $42.04, Implies 20% Upside - TradingView
Qiagen stock (NL0012169213): Shares rise after Q1 update and guidance reaffirmation - AD HOC NEWS
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform - TradingView
Qiagen N.V. stock (NL0012169213): Outlook raised after Q1 2026 update and new AI assistant launch - AD HOC NEWS
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
QIAGEN Discloses Million-Dollar Insider Share Purchase by Supervisory Board Member Trust - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen launches AI assistant for laboratory research By Investing.com - Investing.com South Africa
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows - BioSpace
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Qiagen stock (NL0012169213): Q1 update and share-price backdrop - AD HOC NEWS
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflo - PharmiWeb.com
Qiagen launches AI assistant for laboratory research - Investing.com
New QIAGEN AI lab assistant is designed to speed experiment planning - Stock Titan
QIAGEN launches AI assistant for laboratory workflow support - StreetInsider
Qiagen N.V. stock (NL0012169213): Diagnostics group lifts 2026 outlook after first?quarter earnings - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): steady earnings backdrop as shares lag 2026 highs - AD HOC NEWS
Qiagen (QGEN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
QIAGEN and NVIDIA partner on AI drug discovery - Yahoo Finance
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA - BioSpace
Qiagen stock (NL0012169213): Q1 update keeps diagnostics and life-science demand in focus - AD HOC NEWS
QIAGEN partners with NVIDIA on AI drug discovery platform By Investing.com - Investing.com Nigeria
QIAGEN partners with NVIDIA on AI drug discovery platform - Investing.com UK
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V. - Business Wire
QIAGEN partners with NVIDIA to integrate AI into drug discovery platform - StreetInsider
Bank of America Discloses 2.98% Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen's Digital Insights Business to Integrate Nvidia's BioNeMo Platform - marketscreener.com
Qiagen discloses AFM notification on 2.99% Bank of America stake - TipRanks
Qiagen N.V. stock (NL0012169213): earnings outlook and molecular diagnostics focus - AD HOC NEWS
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $36 - Moomoo
Citigroup downgrades Qiagen NV (QGEN) - MSN
Qiagen N.V. stock (NL0012169213): diagnostics specialist updates investors after Q1 results - AD HOC NEWS
QGEN Maintained by Stifel -- Price Target Lowered to $36 - GuruFocus
Qiagen stock (NL0012169213): New strategic tie-up puts diagnostics in focus - AD HOC NEWS
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stifel cuts Qiagen stock price target to $36 on weaker outlook By Investing.com - Investing.com Australia
Qiagen stock (NL0012169213): QIAGEN’s U.S. diagnostics exposure stays in focus - AD HOC NEWS
Stifel cuts Qiagen stock price target to $36 on weaker outlook - Investing.com Australia
Qiagen NV (QGEN) PT Lowered to $36 at Stifel on 'Lower Growth Outlook' - StreetInsider
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $36 - Moomoo
Qiagen N.V. (QGEN) Investor Outlook: A 32.87% Upside Potential in the Diagnostics & Research Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Qiagen N.V. (QGEN) And Encourages Investors to Connect - ACCESS Newswire
Qiagen N.V. stock (NL0012169213): earnings momentum and diagnostics demand keep investors watching - AD HOC NEWS
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):